Skip to main content
Springer logoLink to Springer
. 2026 Aug 5;69(9):2975–2988. doi: 10.1007/s10840-026-02409-4

Standardised superior vena cava isolation with a balloon-in-basket pulsed-field ablation catheter: feasibility and acute safety of two procedural workflows in 53 consecutive patients

Maciej Wójcik 1,2,✉, Paweł Błaszkiewicz 2, Andrzej Głowniak 1
PMCID: PMC13769749  PMID: 42554910

Abstract

Purpose

Pulsed-field ablation (PFA) is established for pulmonary vein isolation, but data on superior vena cava (SVC) isolation are limited. We assessed the feasibility and acute safety of SVC isolation with the Volt™ balloon-in-basket PFA catheter using two sequentially applied standardised workflows.

Methods

Retrospective single-centre series of 53 consecutive patients undergoing atrial fibrillation ablation with adjunctive SVC isolation. Workflow 1 (n = 28) used phrenic-nerve pacing and tailored energy; Workflow 2 (n = 25) used low-energy PFA only without phrenic pacing; both shared mapping-guided sinus-node sparing and a 20-second flow-preservation manoeuvre. A pre-specified within-platform sensitivity analysis controlled for a concurrent catheter iteration (20 January 2026).

Results

Acute SVC isolation was achieved in all 53 patients (100%, 95% CI 93.3–100%). No phrenic-nerve injury and no permanent atrioventricular block occurred (0/53); one Workflow 1 patient had transient junctional rhythm that resolved spontaneously. Workflow-attributable differences were confined to SVC-specific metrics and persisted within a single catheter-platform era: Workflow 2 used low-energy applications exclusively, required more applications (median 5 vs. 4; p = 0.010), and had a longer SVC isolation time (10.7 vs. 8.5 min; p = 0.006). Shorter procedure and fluoroscopy times in Workflow 2 did not persist within a single catheter-platform era (p = 0.94, p = 0.35). Median follow-up 84 days (data censored 1 July 2026).

Conclusions

SVC isolation with the Volt™ balloon-in-basket PFA catheter is feasible with favourable acute safety. A simplified low-energy-only protocol without phrenic-nerve pacing is a reasonable alternative to a phrenic-paced tailored-energy protocol. Durability and rhythm outcomes require dedicated follow-up study.

Graphical abstract

graphic file with name 10840_2026_2409_Figa_HTML.webp

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s10840-026-02409-4.

Keywords: Pulsed-field ablation, Superior vena cava, Atrial fibrillation, Catheter ablation, Feasibility studies, Phrenic nerve

What’s new?

Largest consecutive single-centre series of SVC isolation with the Volt™ balloon-in-basket catheter (n = 53), more than five-fold larger than the initial workflow report of Tilz and colleagues (n = 10).

Within-platform sensitivity analysis is consistent with the interpretation that apparent gains in procedure and fluoroscopy time reflect operator learning and catheter iteration rather than the workflow change.

Workflow-attributable differences are confined to SVC-specific metrics: exclusive low-energy PFA in Workflow 2, no phrenic-nerve pacing, more applications and longer SVC isolation time.

A simplified low-energy-only workflow without phrenic-nerve pacing achieved 100% acute SVC isolation, with no phrenic-nerve injury and no permanent atrioventricular block, comparable to the tailored-energy workflow with phrenic-nerve pacing.

The study describes a systematic 20-second flow-preservation manoeuvre — motivated by physiological considerations rather than by outcome-controlled data.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s10840-026-02409-4.

Introduction

The superior vena cava (SVC) is a recognised source of atrial arrhythmias and may contribute to both initiation and maintenance of atrial fibrillation (AF) [1–3]. Despite this, SVC isolation is not routinely performed because of concerns regarding injury to adjacent structures, including the phrenic nerve, sinus node, and atrioventricular conduction system, and is not routinely recommended in current AF ablation consensus documents [3, 4].

Pulsed-field ablation (PFA), a non-thermal ablation modality based on electroporation, has gained clinical use because of its myocardial selectivity and favourable safety profile [5–8]. Clinical experience with the balloon-in-basket PFA platform has demonstrated feasibility and safety for pulmonary vein isolation [9, 10]. However, evidence supporting PFA for non-pulmonary vein targets, including the SVC, remains limited [11–14].

We aimed to evaluate the feasibility and safety of SVC isolation using the Volt™ balloon-in-basket PFA catheter, with particular emphasis on a standardised procedural workflow incorporating electroanatomical mapping, phrenic-nerve monitoring, tailored energy delivery, and preservation of SVC flow.

Methods

Study population

This retrospective single-centre series included 53 consecutive patients undergoing catheter ablation for atrial fibrillation with adjunctive SVC isolation. Patients with paroxysmal, persistent, or long-standing persistent AF were included. In the initial phase of the study, SVC isolation was performed at the operator’s discretion; the institutional approach subsequently evolved to routine adjunctive isolation of all major thoracic-vein triggers (all four pulmonary veins and the SVC) in consecutive patients undergoing atrial-fibrillation ablation with this platform. Baseline clinical and echocardiographic data were obtained from institutional records. Ethics approval, consent to participate, and consent for publication are stated in the corresponding end-of-manuscript section.

Ablation procedure

All procedures were performed with the balloon-in-basket Volt™ PFA System (Abbott Laboratories, Abbott Park, IL, USA), used for mapping, ablation, and validation. The system comprises a 12.5-French balloon-in-basket catheter with 8 nitinol splines equally distributed around the circumference of an internal compliant balloon (expanded diameter 28 mm). Each spline functions as a single elongated active electrode with an exposed length of 17.7 mm, and the catheter integrates directly with the EnSite™ X three-dimensional electroanatomical mapping system (Abbott Laboratories) for mapping, ablation, and validation within a single platform. Pulsed-field energy is delivered as biphasic, bipolar pulse trains between adjacent splines; standard (nominal) PFA applications were delivered at 1,700 V (10 bursts per application) and low-energy PFA applications at 1,345 V (10 bursts per application). From 20 January 2026 onward, an improved iteration of the Volt™ catheter was introduced at our centre, which allowed faster and smoother cannulation of the right inferior pulmonary vein and is expected to contribute to overall procedural efficiency. Transoesophageal echocardiography was performed in all patients prior to the procedure to exclude intracardiac thrombus. Vitamin K antagonists were continued within the therapeutic INR range (2.0–3.0), and direct oral anticoagulants were withheld on the morning of the procedure. Procedures were conducted under general anaesthesia or intravenous sedation using fentanyl and remimazolam, according to institutional practice. Two right femoral venous accesses were obtained under ultrasound guidance. Transseptal access was achieved using an 8.5-F SL0 fixed sheath (Abbott), subsequently exchanged for a 13-F steerable introducer (Agilis™ NxT, Abbott) for delivery of the Volt™ catheter into the left atrium. Intravenous unfractionated heparin was administered to maintain an activated clotting time of 350–400 s throughout the procedure, including the SVC ablation phase. Antral pulmonary vein isolation was performed according to our standard technique [9, 10], with at least two rotational PFA applications per vein at the nominal energy setting (1,700 V); when phrenic-nerve capture was observed during right pulmonary vein isolation, the energy level was reduced to the low-energy setting (1,345 V). Additional ablation was performed when clinically indicated (Fig. 1).

Fig. 1.

Fig. 1

Workflow 1 procedural metrics over chronological order, illustrating the combined effect of operator learning curve and catheter platform progress. (A) Scatter of total procedure time for all 28 Workflow 1 patients plotted against the date of the index procedure. Red circles represent patients ablated before 20 January 2026 with the first-generation Volt™ catheter (n = 16); blue squares represent patients ablated from 20 January 2026 onward with the improved iteration of the Volt™ catheter (n = 12). A 5-point centred rolling median is shown as a grey trend line. Horizontal reference lines indicate the era-specific medians (88.5 min before 20 January 2026; 62.5 min thereafter). (B) Box-plot comparison of total procedure time in the three relevant cohorts: Workflow 1 before 20 January 2026 (first-generation catheter, n = 16), Workflow 1 from 20 January 2026 onward (improved catheter, n = 12), and Workflow 2 (all from 20 January 2026, improved catheter, n = 25). Boxes show the interquartile range, with the horizontal line at the median and whiskers extending to 1.5×IQR; individual outliers are shown as open circles. (C) Scatter of fluoroscopy time for all 28 Workflow 1 patients plotted against the date of the index procedure, using the same colour coding as Panel A. Horizontal reference lines indicate the era-specific medians (15.4 min before 20 January 2026; 6.8 min thereafter). The within-Workflow-1 reduction in fluoroscopy time across the catheter platform transition (15.4 → 6.8 min, with the workflow itself unchanged) corroborates the analogous reduction in total procedure time shown in Panels A and B, providing convergent evidence that the broader procedural-efficiency gains observed during the study period reflect predominantly operator learning curve and catheter platform progress rather than the workflow change itself

Step-by-step SVC isolation protocol

The following stepwise protocol is summarised graphically in Fig. 2. Steps 1–8, 11–13, 16 and 17 are common to both workflow variants; the two variants differ only in Steps 9–10 (whether phrenic-nerve pacing is performed before the first application) and in Steps 14–15 (whether nominal-energy or low-energy PFA is delivered).

Fig. 2.

Fig. 2

Stepwise SVC isolation protocol with the Volt™ balloon-in-basket pulsed-field ablation catheter — procedural flow diagram. The diagram summarises the 17-step protocol described in Methods, with branching at the first PFA application into Workflow 1 (tailored-energy with phrenic-nerve pacing; left, red) or Workflow 2 (low-energy only without phrenic-nerve pacing; right, blue). Steps common to both workflows are centred (light blue). Decision points are shown as diamonds (yellow). The two workflow paths converge at Step 16 (repetition until complete circumferential isolation, with continuous ECG and intracardiac electrogram monitoring) and at Step 17 (verification by voltage mapping and entrance/exit-block pacing manoeuvres). All 53 consecutive patients achieved complete circumferential SVC isolation. No phrenic-nerve injury or permanent atrioventricular block was observed. One Workflow 1 patient developed transient junctional rhythm immediately during SVC isolation, consistent with transient sinus-node dysfunction; this resolved spontaneously without intervention

Common initial steps (steps 1–8): catheter positioning, mapping, and sinus-node identification

  • Step 1. A diagnostic guide-wire is advanced deeply into the SVC to stabilise the Volt™ catheter during all subsequent manoeuvres in the SVC.

  • Step 2. The Volt™ catheter, partially inflated with 7 mL (of a maximum 10 mL), is advanced deeply into the SVC, beyond the area of visible local electrograms recorded from the Volt™ splines.

  • Step 3. Balloon inflation is then completed to achieve full Volt-to-SVC wall contact (final inflation volume 8–10 mL depending on individual SVC diameter); contact is confirmed by impedance measurement of the Volt™ catheter visualised on EnSite™ X.

  • Step 4. Slow activation mapping of the SVC–right atrial (RA) junction is performed on EnSite™ X during sinus rhythm using the first-deflection criterion. In the presence of ectopic beats, manual annotation is restricted to sinus beats only; this produces a reliable activation map of the sinus-node region based exclusively on sinus rhythm or sinus beats. Without this safeguard, sinus-node localisation may be inaccurate, with consequent risk of sinus-node injury during subsequent PFA delivery. For a representative example of the LAT first-deflection annotation method, see Fig. 3, Panels A, C and D (and Panel B for mechanical AF induction observed during SVC catheter manipulation in a representative case).

  • Step 5. The Volt™ catheter is then gradually withdrawn down the SVC towards the SVC–RA junction to precisely map the sinus-node region and the SVC–RA junction.

  • Step 6. On completion of mapping, the sinus-node region is confirmed using the EnSite™ X LAT activation map together with the propagation (white-purple) map. (Fig. 3, Panels D1 — LAT activation map — and D2 — matched LAT propagation map).

  • Step 7. The Volt™ catheter (still partially inflated) is then re-advanced into the SVC above the sinus-node region, into the segment where electrical isolation will be performed (the area in which PFA applications will be delivered). (Fig. 3, Panel A illustrates the resulting Volt™ catheter position within the SVC.)

  • Step 8. At the site of the first PFA application, the balloon is fully inflated (8–10 mL) to achieve full Volt-to-SVC wall contact, confirmed by impedance measurement visualised on EnSite™ X.

Fig. 3.

Fig. 3

Procedural workflow for superior vena cava (SVC) isolation with the Volt™ balloon-in-basket pulsed-field ablation (PFA) catheter — multi-panel composite (A1 → H3). Common colour key for all electrogram tracings (Panels B, C, G): white = surface 12-lead ECG; yellow = bipolar electrograms from the 10-pole coronary sinus (CS) catheter; green = bipolar electrograms from the splines of the Volt™ PFA catheter. Three-dimensional reconstructions were obtained with the EnSite™ X EP System (Abbott, Plymouth, MN, USA). A — Three-dimensional electroanatomical local activation time (LAT) mapping during sinus rhythm using the EnSite™ X EP System. Local activation time annotated at the earliest near-field atrial electrogram deflection to identify the site of earliest atrial activation, corresponding to the presumed sinus-node exit region. LAT first-deflection map (A1) and corresponding EnSite™ X LAT propagation map (A2) with the EnSite™ X LivePoint™ display (the EnSite™ X feature that renders the live point cloud of mapped electrogram positions, with each point colour-coded by validity) illustrating surface reconstruction density. Anatomical context: postero-lateral views of the right-atrial (RA)–SVC junction with the Volt™ balloon-in-basket catheter advanced above the RA roof and inflated within the SVC; the eight splines (green markers) are in contact with the SVC wall. B — Mechanical induction of atrial fibrillation (AF) during SVC mapping. B1 → B3. Three sequential 3D maps of the SVC with the Volt™ catheter in situ; each sub-panel shows the same reconstruction in paired anterior (left) and posterior (right) views. The simultaneous surface and intracardiac electrograms displayed beneath the maps document the transition from sinus rhythm to SVC-driven activity and finally to fully disorganised, high frequency atrial activity recorded synchronously on the green Volt™ splines and the yellow CS catheter — providing the mechanistic rationale for empirical SVC isolation in selected patients. C — Sinus-node localisation using a three-dimensional sinus-rhythm LAT map during ectopic triggers. The earliest near-field atrial electrogram deflection was manually annotated to identify the earliest atrial activation site at the superior right atrium / SVC–RA junction. C1. Anterior-view LAT (first-deflection) map of the SVC; white coding marks the area of earliest local activation (manual annotation), identifying the location of the sinus node. C2. Corresponding intracardiac tracings. The first two ectopic beats were not used for activation mapping. The earliest local activation on the green Volt™ spline electrodes was annotated manually during sinus rhythm; the white arrow marks the beat used for annotation. D — Pre-procedural sinus-node localisation by LAT activation and propagation mapping. D1. Three-dimensional sinus-rhythm LAT map of the SVC–RA junction in anterior view. The colour gradient (white = earliest) identifies the sinus-node location (sinus-node exit region) as the site of first surface-P-wave deflection. The "SVC" label indicates the cranial end of there construction. D2. Matched LAT propagation map (anterior view) on the same geometry, showing a centrifugal pattern of activation originating from the sinus-node region (purple wavefront). This preprocedural step defines the protected zone that must be spared during energy delivery. E — Per-application footprint of nominal- vs low-energy PFA. E1. Workflow 1 — nominal-energy PFA: two side-by-side reconstructions (anterior view on the left; superior view on the right) showing a broader transmural contact footprint between the Volt™ splines and the SVC wall after the second PFA application. E2. Workflow 2 — low-energy PFA: matched paired views (anterior on the left; superior on the right) showing the smaller per-application footprint, requiring a minimum of three sequential low-energy applications with intervening rotations for circumferential coverage of the SVCostium. The colour legend on the left (Volt™ PFA: Optimal / Sub-optimal / Not available) refers to per-electrode contact quality and is identical in both sub-panels. F — Post-PFA SVC reconstruction with the Volt™ catheter withdrawn into the RA. F1. Paired views (right-lateral on the left; superior on the right) immediately after the second PFA application, with the Volt™ basket in the last PFA-application position. F2. Repeat paired views (right-lateral on the left; superior on the right) of the same SVC–RA junction showing the catheter retracted into the right atrium to allow blood flow through the SVC(the SVC was blocked by the Volt™ catheter during the application). The shadow of the Volt™ catheter (captured during the first PFA application) allows the next application to be performed at the same location within the SVC. G — Single SVC-isolation-attributable safety event: transient junctional rhythm in one Workflow 1 patient during the second PFA application in the SVC. G1. Posterior-view 3D voltage map of the SVC–RA junction at the moment of energy delivery; the Volt™ basket is fully deployed. G2. Matched superior view at the time-point of the PFA event; the Volt™ basket position is unchanged, demonstrating mechanical stability. G3 → G9. Continuous synchronised electrogram strips spanning the application — white =surface 12-lead ECG, yellow = 10-pole CS, green = Volt™ PFA splines. The traces show an abrupt transition from atrial tachycardia at cycle length 396 ms (G3) through progressively prolonged cycle lengths (G4: 422 ms) to sinus-node arrest (G5: 1,728 ms; PFA was stopped at this point), followed by sinus bradycardia (G6: 983 ms) and then junctional rhythm (G7: 1,352ms; G8: 1,238 ms; G9: 1,127 ms). The event resolved spontaneously without intervention and did not recur. No permanent sinus-node dysfunction was observed at discharge or at follow-up; this was the sole SVC-isolation-attributable complication in the series. H — Pre- and post-isolation voltage / LAT activation mapping with eField overlay. (eField = the EnSite™ X graphical marker indicating the planned PFA delivery footprint relative to there constructed anatomy.) H1. Pre-isolation bipolar voltage map of the SVC (anterior view). The body of the SVC shows preserved bipolar voltage (purple, > 0.50 mV; scale on the left). The cyan band at the SVC–RA junction marks the performed PFA delivery / eField target zone, positioned cranial to the sinusnode region and just above the cavo-atrial junction. H2. LAT activation map acquired during sinus rhythm on the same geometry (anterior view).The small white zone in the mid-SVC corresponds to the earliest local activation (first-deflection annotation); the white arrow indicates the anatomical sinus node. The cyan eField target is positioned clearly cranial to the sinus-node region, demonstrating intentional sinus-node sparing.H3. Post-isolation voltage re-map (anterior view). The grey, electrically silent band immediately cranial to the cyan eField zone confirms circumferential loss of recordable bipolar voltage (acute circumferential isolation), while the caudal part of the SVC below the cyan eField zone retains preserved (purple) voltage. Together, H1 → H3 demonstrate the standardised plan used to (i)plan the ablation line, (ii) confirm sinus-node sparing, and (iii) document acute circumferential SVC isolation. Abbreviations: AF = atrial fibrillation; CS = coronary sinus; ECG = electrocardiogram; LAT =local activation time; PFA = pulsed-field ablation; RA = right atrium; SVC = superior venacava

Workflow branch (steps 9–15): phrenic-nerve pacing and energy-tailoring track (workflow 1) versus low-energy-only track (workflow 2)

  • Step 9 (Workflow 1). With confirmed full Volt-to-SVC contact and stable catheter position, phrenic-nerve stimulation is performed sequentially from each of the eight Volt™ splines at 20 mA / 1 ms pulse width and a pacing cycle length of 1,000 ms. If no phrenic-nerve capture is observed from any spline, the first PFA application is delivered from all Volt™ splines at the nominal energy setting (1,700 V; 10 bursts). If phrenic-nerve capture is observed from at least one spline, the first (and all subsequent) applications are delivered at the low-energy setting (1,345 V; 10 bursts). The 20 mA output lies within the high-output range used for phrenic-nerve capture testing during cryoballoon pulmonary vein isolation [15]; in the present protocol it was delivered at a 1 ms pulse width and adapted to the Volt™ platform by sequential per-spline pacing, mirroring the VOLT CE Mark methodology [9]. This pacing protocol is an off-label use of the Volt™ catheter and has not been validated by the manufacturer; it is reported here as the institutional practice that informed Workflow 1.

  • Step 10 (Workflow 2). Phrenic-nerve pacing is not performed. With confirmed full Volt-to-SVC contact and stable catheter position, the first PFA application is delivered at the low-energy setting (1,345 V; 10 bursts).

  • Step 11. During or immediately after the first PFA application — with the Volt™ catheter still in its stable SVC position — a shadow of the catheter position at this site is recorded on EnSite™ X. This shadow is used to guide spline-position adjustment for subsequent applications. (Fig. 3, Panel F2 illustrates the Volt™ catheter shadow used to guide repeated applications.)

  • Step 12. After completion of the application the Volt™ catheter is withdrawn into the right atrium for 20 s to restore blood flow through the SVC (during each PFA application the SVC is completely occluded by the inflated balloon).

  • Step 13. The Volt™ catheter is then re-advanced into the SVC, returning to the site marked by the previously recorded shadow, and re-inflated to full Volt-to-SVC contact (8–10 mL; confirmed by impedance measurement on EnSite™ X). Spline positioning is rotated slightly relative to the prior application so that subsequent applications cover SVC-wall segments not yet ablated, with the goal of achieving complete circumferential SVC isolation.

  • Step 14 (Workflow 1, nominal-energy track). If the first application was delivered at nominal energy (no phrenic-nerve capture in Step 9), phrenic-nerve stimulation is repeated at the new spline position. If phrenic-nerve capture is again absent, the next application is delivered at nominal energy.

  • Step 15 (Workflow 1, low-energy track; and Workflow 2). If the first application was delivered at low energy (phrenic-nerve capture observed in Step 9, or Workflow 2), phrenic-nerve stimulation is not repeated. Subsequent applications are delivered at low energy with slightly rotated spline positioning to cover not-yet-ablated SVC-wall segments and ultimately achieve complete circumferential SVC isolation.

Common closing steps (steps 16–17): iteration to complete circumferential isolation and post-procedural verification

  • Step 16. Steps 12–15 are repeated until complete circumferential SVC isolation is achieved. Throughout every SVC application the surface electrocardiogram and intracardiac electrograms on the electrophysiology recording system are monitored continuously; PFA delivery is interrupted immediately in the event of any suspicion of sinus-node injury or other adverse electrophysiological event. Sinus-node injury was defined as sinus arrest, severe sinus bradycardia (< 40 bpm), or onset of junctional rhythm. Phrenic-nerve stunning was defined as sudden loss of diaphragmatic contraction during the procedure (weakening or loss of diaphragmatic movement detected either by palpation or by fluoroscopic imaging). Permanent atrioventricular block was defined as new second- or third-degree atrioventricular block persisting to hospital discharge or requiring permanent pacemaker implantation.

  • Step 17. After completion of SVC isolation (in our cohort: minimum 2 and maximum 9 PFA applications per patient), voltage mapping of the SVC is performed on EnSite™ X to confirm electrical isolation. In addition, pacing is performed from the SVC at a site above the isolation line to confirm exit block. In every patient the SVC segment above the isolation line was electrically silent on voltage mapping, and no spontaneous SVC electrical activity was observed. Pacing from this segment failed to capture the left atrium: there was no LA activation after each stimulus, no coronary-sinus electrogram response synchronous with the pacing rate, and no resetting of the sinus rhythm. The plan-execute-verify mapping sequence is illustrated in Fig. 3, Panel H (H1: pre-isolation voltage map; H2: LAT confirming intentional sinus-node sparing; H3: post-isolation voltage re-map confirming circumferential electrical silence).

Rationale for the two workflow variants

Workflow 1 (phrenic-nerve pacing performed sequentially from all eight Volt™ splines before each nominal-energy application) prolongs the duration of SVC flow blockade per application cycle (pacing screening plus PFA delivery), but typically requires fewer PFA applications to achieve complete circumferential isolation because nominal-energy applications produce wider lesions. In our cohort, a minimum of two nominal-energy applications was required to achieve complete SVC isolation; the maximum number was determined by individual SVC diameter and lesion gap. Workflow 2 (a priori low-energy PFA only, no phrenic-nerve pacing) shortens each application cycle (no pacing screening) but requires a greater number of low-energy applications to achieve complete circumferential isolation. A minimum of three low-energy applications was required in our cohort; with each additional application a further 20-second SVC-flow-restoration pause between applications is added, so the total time dedicated to SVC isolation tends to be modestly longer in Workflow 2 than in Workflow 1. The choice between the two workflows therefore involves a trade-off between safety margins (phrenic-nerve screening, at the cost of prolonged SVC occlusion per application cycle) and procedural efficiency (fewer pacing manoeuvres at the cost of more low-energy applications); both achieved 100% acute electrical isolation in the present cohort, with no phrenic-nerve injury and no permanent atrioventricular block in either group.

Statistical analysis

Continuous variables are presented as median and interquartile range (IQR), and categorical variables as counts and percentages. Between-group comparisons (Workflow 1 vs. Workflow 2) were performed using the Mann–Whitney U test (exact, two-tailed) for continuous variables, Fisher’s exact test (two-sided) for 2 × 2 categorical variables, and the chi-square test for the 2 × 3 categorical comparison of AF type. Hodges-Lehmann estimators of the difference of medians are reported alongside the medians as a non-parametric effect-size measure for selected continuous comparisons. 95% confidence intervals for proportions (acute success and safety event rates) were calculated using the Clopper–Pearson exact method. A two-sided p-value < 0.05 was considered statistically significant. Given the exploratory, feasibility-focused design of the study and the large number of comparisons performed across baseline and procedural variables, no formal correction for multiple comparisons was applied; p-values should therefore be interpreted descriptively rather than as hypothesis-confirming. Notably, the primary workflow-attributable comparisons — the number of SVC applications and the total SVC isolation time — were significant at levels (full cohort p = 0.010 and p = 0.006; within a single catheter-platform era p = 0.002 and p = 0.012) that would remain significant under conventional correction for the number of procedural comparisons, whereas the borderline baseline and secondary comparisons would not. With the available sample sizes (Workflow 1, n = 28; Workflow 2, n = 25), the study has approximately 80% power at α = 0.05 to detect a between-group shift of roughly 0.8 standard deviations for continuous variables and approximately 40% points for binary outcomes; it is therefore not powered to detect smaller differences. Analyses were performed in GraphPad Prism 11 (GraphPad Software, San Diego, CA, USA). A complete statistical workbook containing the per-patient dataset, per-group descriptive statistics, and the underlying calculations supporting every value reported in Tables 1 and 2 is provided as Supplementary Material (Supplementary File S1).

Table 1.

Baseline characteristics (n = 53)

Characteristic All (n = 53) Workflow 1 (n = 28) Workflow 2 (n = 25) p-value
Age, years 69.1 (59.9–75.4) 69.9 (59.9–76.7) 67.0 (59.3–72.9) 0.244
Female sex, n (%) 24 (45%) 14 (50%) 10 (40%) 0.583
AF type — PAF, n (%) 13 (25%) 6 (21%) 7 (28%) 0.751
AF type — persistent, n (%) 31 (58%) 18 (64%) 13 (52%) 0.413
AF type — long-standing persistent, n (%) 9 (17%) 4 (14%) 5 (20%) 0.720
AF duration, years 5 (2–8) 5.5 (2–11) 4 (2–6) 0.197
CHA₂DS₂-VASc score 3 (2–4) 3 (2–4) 2 (2–4) 0.238
Body mass index, kg/m² 27.6 (25.9–32.3) 27.6 (25.9–30.7) 27.6 (25.5–32.4) 0.624
Left atrial diameter, mm 45 (41–50) 45.5 (42–50) 44 (40–49) 0.543
LVEF, % 60 (55–60) 59 (52–60) 60 (55–60) 0.379
EHRA (symptom class) 2 (2–3) 2 (2–3) 2 (2–2) 0.935
Prior AF ablation, n (%) 9 (17%) 3 (11%) 6 (24%) 0.279

Table 2.

Procedural characteristics

Characteristic All (n = 53) Workflow 1 (n = 28) Workflow 2 (n = 25) Hodges-Lehmann (W2 − W1) p-value
Sedation (fentanyl + remimazolam), n (%) 50 (94%) 26 (93%) 24 (96%) — > 0.999
General anaesthesia, n (%) 3 (6%) 2 (7%) 1 (4%) — > 0.999
Pulmonary vein isolation, n (%) 53 (100%) 28 (100%) 25 (100%) — —
SVC isolation attempted, n (%) 53 (100%) 28 (100%) 25 (100%) — —
SVC isolation achieved, n (%) 53 (100%) 28 (100%) 25 (100%) — —
Rhythm during SVC ablation — sinus rhythm, n (%) 52 (98%) 27 (96%) 25 (100%) — —
Rhythm during SVC ablation — atrial tachycardia, n (%) 1 (2%) 1 (4%) 0 (0%) — —
Procedure time, min 65 (60–85) 78.5 (60–100) 65 (55–70) −15.0 0.025
Fluoroscopy time, min 10.5 (7.0–13.3) 12.7 (7.8–16.0) 8.2 (6.8–10.9) −2.95 0.020
Fluoroscopy dose, mGy 60.1 (37.3–88.5) 62.1 (48.2–97.3) 51.6 (30.8–82.5) −10.9 0.294
SVC PFA applications per patient 4 (3–5) 4 (3–5) 5 (4–5) + 1.0 0.010
SVC isolation time, min 9.9 (8.3–11.1) 8.5 (7.6–10.5) 10.7 (9.7–11.7) + 1.79 0.006
SVC energy delivery — low-energy only, n (%) 37 (70%) 12 (43%) 25 (100%) — < 0.001
SVC energy delivery — nominal/standard, n (%) 16 (30%) 16 (57%) 0 (0%) — < 0.001
Phrenic-nerve pacing performed, n (%) 28 (53%) 28 (100%) 0 (0%) — < 0.001
Phrenic-nerve capture (among paced), n/N (%) 12/28 (43%) 12/28 (43%) n/a — —
Cardioversion, n (%) 25 (47%) 11 (39%) 14 (56%) — 0.276
Low-voltage area / extra-PV ablation, n (%) 17 (32%) 12 (43%) 5 (20%) — 0.088
Cavotricuspid isthmus ablation, n (%) 13 (25%) 9 (32%) 4 (16%) — 0.213

The Hodges-Lehmann estimator is the median of all pairwise differences between the two groups; it is a non-parametric effect-size measure and is not, in general, equal to the difference of the two group medians

Results

Baseline characteristics for the overall cohort and the two workflow subgroups are summarised in Table 1. The median age was 69.1 years (IQR 59.9–75.4), and 24 patients (45%) were female. Most patients had persistent or long-standing persistent AF (31 patients [58%] and 9 patients [17%], respectively), and 9 patients (17%) had undergone prior pulmonary vein isolation. Median AF duration was 5.0 years (IQR 2.0–8.0), and the median CHA₂DS₂-VASc score was 3 (IQR 2–4). Baseline clinical and echocardiographic characteristics did not differ significantly between Workflow 1 and Workflow 2 subgroups (all p > 0.05).

Indications and mechanistic context. Adjunctive SVC isolation was prompted in individual patients by documented spontaneous SVC-origin ectopy or SVC-driven tachycardia observed during the procedure on intracardiac electrograms, with confirmation by activation or entrainment mapping when sustained tachycardia was present. Nine patients underwent the index procedure as a redo for previously failed pulmonary vein isolation (five prior radiofrequency and four prior cryoballoon procedures). In one patient, SVC isolation was anatomically indicated by anomalous drainage of the right superior pulmonary vein into the SVC (a partial anomalous pulmonary venous connection); the four low-energy applications used to isolate the SVC at the cavo-atrial junction therefore also electrically isolated the anomalously draining pulmonary vein. High-dose isoproterenol provocation was not performed routinely, and per-patient trigger documentation was not systematic in the early discretionary phase; the true prevalence of latent SVC triggers in this cohort is therefore unascertained.

Procedural characteristics, including a comparison between the two workflows, are shown in Table 2. Pulmonary vein isolation and SVC isolation were successfully performed in all 53 patients (100%). SVC isolation was achieved in 100% of cases in both subgroups and confirmed by mapping and pacing.

Most procedures were performed in sinus rhythm, with one case performed during incessant SVC atrial tachycardia. Median procedure time for the overall cohort was 65 min (IQR 60–85), and median fluoroscopy time was 10.5 min (IQR 7.0–13.3). Total procedure time was shorter in the Workflow 2 cohort (median 65 min, IQR 55–70) than in the Workflow 1 cohort (median 78.5 min, IQR 60–100; Hodges-Lehmann difference − 15.0 min; p = 0.025), as was fluoroscopy time (median 8.2 min, IQR 6.8–10.9 vs. 12.7 min, IQR 7.8–16.0; Hodges-Lehmann difference − 2.95 min; p = 0.020). Within Workflow 1, the median procedure time fell from 88.5 min (IQR 73.8–125.0) in the 16 patients ablated before 20 January 2026 to 62.5 min (IQR 57.5–80.2) in the 12 patients ablated from that date onward, despite the workflow itself being unchanged (Fig. 1, Panels A–C). Interpretation of these temporal differences is discussed below.

Additional ablation beyond pulmonary vein isolation was performed in a subset of patients. Low-voltage area or extra-pulmonary-vein ablation was carried out in 17 patients (32%), cavotricuspid isthmus ablation in 13 patients (25%), and cardioversion was required in 25 patients (47%).

SVC isolation was performed using two sequential standardised workflows: Workflow 1 (Table 3, left column), incorporating mapping-guided sinus-node localisation, systematic phrenic-nerve pacing, tailored energy delivery, and preservation of venous flow; and Workflow 2 (Table 3, right column), employing mapping-guided low-energy pulsed-field ablation only, without phrenic-nerve pacing. The per-application footprint of nominal-energy Workflow 1 versus low-energy Workflow 2 applications is illustrated in Fig. 3, Panels E1 and E2 respectively.

Table 3.

Side-by-side comparison of the two standardised workflows for SVC isolation with the Volt™ balloon-in-basket pulsed-field ablation catheter

Workflow component Workflow 1 (mapping + phrenic-nerve pacing + tailored energy) Workflow 2 (mapping + low-energy only, no phrenic-nerve pacing)
Electroanatomical mapping 3D mapping of the SVC–RA junction on EnSite™ X 3D mapping of the SVC–RA junction on EnSite™ X
Sinus-node localisation EnSite™ X 3D activation map, first-deflection criteria; energy avoided in this region EnSite™ X 3D activation map, first-deflection criteria; energy avoided in this region
Phrenic-nerve protection High-output bipolar pacing (20 mA at 1 ms pulse width) from each of the 8 V™ splines prior to each application Phrenic-nerve pacing not performed; protection relies on the neural sparing of pulsed-field energy combined with systematic low-energy delivery
Energy delivery Nominal 1,700 V (10 bursts per application) when no phrenic-nerve capture; reduced to 1,345 V (low energy, 10 bursts per application) if phrenic-nerve capture present Low energy 1,345 V (10 bursts per application) in all applications
Catheter rotation Rotational repositioning of the catheter between applications to ensure circumferential coverage at the SVC–RA junction Rotational repositioning of the catheter between applications to ensure circumferential coverage at the SVC–RA junction
SVC occlusion Transient during each application Transient during each application
Flow preservation Catheter withdrawal into the right atrium for approximately 20 s between consecutive applications Catheter withdrawal into the right atrium for approximately 20 s between consecutive applications
Minimum PFA applications for complete circumferential isolation 2 nominal-energy applications (more if SVC diameter requires) 3 low-energy applications (more if SVC diameter requires)
Endpoint Complete circumferential SVC isolation, confirmed by voltage mapping (electrical silence) and entrance/exit-block pacing manoeuvres Complete circumferential SVC isolation, confirmed by voltage mapping (electrical silence) and entrance/exit-block pacing manoeuvres

The differences directly attributable to the workflow change itself were observed in the SVC-specific metrics. The median number of PFA applications required to achieve SVC isolation was 4 per patient (IQR 3–5) overall, with a small but statistically significant increase in Workflow 2 (median 5, IQR 4–5) compared with Workflow 1 (median 4, IQR 3–5; Hodges-Lehmann difference + 1.0 application; p = 0.010). Low-energy PFA was used exclusively in all Workflow 2 patients (25/25, 100%) and selectively in Workflow 1 (12/28, 43%; p < 0.001 for nominal versus low-energy use between groups). Consistent with the systematic use of low-energy applications, the total time dedicated to SVC isolation (encompassing sinus-node mapping, phrenic-nerve pacing when performed, PFA applications, the 20-second pauses for catheter withdrawal, and final voltage re-mapping) was modestly longer in Workflow 2 than in Workflow 1 (median 10.7 min, IQR 9.7–11.7 vs. 8.5 min, IQR 7.6–10.5; Hodges-Lehmann difference + 1.79 min; p = 0.006). The time saved by omitting phrenic-nerve pacing in Workflow 2 was therefore offset by the additional low-energy applications required to achieve complete circumferential SVC isolation, together with the additional time for the repeated 20-second flow-preservation manoeuvres between applications, and the net workflow-attributable effect on SVC isolation time was a modest increase rather than a decrease. Three-dimensional electroanatomical mapping guidance was applied in all procedures.

Sensitivity analysis controlling for catheter platform

To isolate the workflow effect from the catheter platform change, we repeated the principal comparisons restricted to patients ablated from 20 January 2026 onward — the era during which only the improved Volt™ catheter was used. This within-platform comparison included Workflow 1 patients ablated from 20 January 2026 onward (n = 12) and all Workflow 2 patients (n = 25). Total procedure time did not differ (62.5 min, IQR 57.5–80.2 vs. 65.0 min, IQR 55.0–70.0; p = 0.94), nor did fluoroscopy time (6.8 min, IQR 5.8–10.7 vs. 8.2 min, IQR 6.8–10.9; p = 0.35). The SVC-specific differences persisted within this single catheter-platform era: Workflow 2 required more SVC PFA applications per patient than Workflow 1 (median 5, IQR 4–5 vs. 3.5, IQR 3–4; p = 0.002), used low-energy applications exclusively (25/25, 100% vs. 5/12, 42%; p < 0.001), and had a longer total SVC isolation time (10.7 min, IQR 9.7–11.7 vs. 8.0 min, IQR 7.3–9.4; p = 0.012). The interpretation of these findings is presented in the Discussion.

Acute SVC isolation was achieved in all patients (53/53, 100%; 95% CI 93.3–100%), with confirmation by voltage mapping and pacing manoeuvres in both subgroups (28/28 in Workflow 1 and 25/25 in Workflow 2). No procedural failures were observed. Acute success was uniform across AF subtypes — paroxysmal AF (13/13, 100%), persistent AF (31/31, 100%), and long-standing persistent AF (9/9, 100%) — consistent with feasibility of SVC isolation across the AF phenotypes represented in this cohort.

Safety and follow-up

No major complications occurred. No phrenic-nerve stunning, no persistent phrenic-nerve injury, and no permanent atrioventricular block were observed (0/53; 95% CI 0–6.7%; Workflow 1 0/28, 95% CI 0–12.3%; Workflow 2 0/25, 95% CI 0–13.7%). One patient (Workflow 1) developed transient junctional rhythm immediately during SVC isolation, consistent with transient sinus-node dysfunction; this resolved spontaneously without intervention and did not recur. This was the only SVC-isolation–attributable electrophysiological event in the cohort. The acute safety findings were assessed over a median follow-up of 84 days (IQR 50–196; range 35–246 days; data censored 1 July 2026); the most recently treated patients contributed shorter follow-up at the time of analysis. The continuous synchronised electrogram recordings spanning this event, with the corresponding Volt™ catheter position in the SVC, are shown in Fig. 3, Panel G (panels G1–G2 and electrogram strips G3–G9).

Patients were followed clinically after discharge to monitor for late safety events. No delayed atrioventricular conduction disturbances and no cases of phrenic-nerve dysfunction were observed during clinical follow-up in either workflow subgroup. We emphasise that, because Workflow 2 comprises the most recent consecutive patients in the series, the safety profile reported here for that subgroup represents the early post-procedural period only (in-hospital observation and short-term clinical contact); a longer follow-up will be required to confirm the absence of late events.

Discussion

This study shows that SVC isolation with the Volt™ balloon-in-basket PFA catheter is feasible, reproducible, and associated with a favourable acute safety profile in a consecutive real-world cohort of 53 patients. Acute SVC isolation was achieved in all patients, with no phrenic-nerve injury and no permanent atrioventricular block; one transient electrophysiological event attributable to SVC isolation — junctional rhythm consistent with transient sinus-node dysfunction in one Workflow 1 patient — resolved spontaneously without intervention. The study describes two sequential standardised workflows that share systematic preservation of SVC flow and compares a phrenic-paced tailored-energy protocol (Workflow 1) with a simplified low-energy-only protocol (Workflow 2).

Comparison with prior literature

Recent studies have demonstrated the feasibility of SVC isolation using PFA, including pentaspline systems, intracardiac echocardiography (ICE)-guided workflows, and early balloon-in-basket experiences [11–14] (side-by-side comparison in Table 4). Although substantially larger SVC-isolation cohorts have been reported with the pentaspline pulsed-field catheter (Ollitrault et al., n = 105; Pierucci et al., n = 616) [11, 12], clinical experience with the balloon-in-basket platform remains limited to small reports. Our study extends this literature in four specific ways. First, to our knowledge it is the largest consecutive single-centre series of SVC isolation with the Volt™ balloon-in-basket catheter reported to date (n = 53), more than five-fold larger than the initial workflow report of Tilz and colleagues (n = 10) [14] and substantially larger than the recent technical note by Papakonstantinou and O’Brien [13]. Second, it is the first report, to our knowledge, to perform a within-cohort comparison of two distinct standardised workflows for balloon-in-basket SVC isolation — a phrenic-paced tailored-energy protocol (Workflow 1) and a simplified low-energy-only protocol without phrenic-nerve pacing (Workflow 2) — and to identify which differences are workflow-attributable versus which reflect operator learning and catheter platform progress. Third, it explicitly describes and quantifies a flow-preservation manoeuvre (systematic catheter withdrawal into the right atrium for approximately 20 s between applications) that is not emphasised in prior reports of this device. Fourth, it includes a sensitivity analysis restricting the comparison to patients ablated within a single catheter platform era, which strengthens the inferences about which workflow elements drive procedural differences.

Table 4.

Comparison of the present series with prior reports of SVC isolation using pulsed-field ablation

Study Device / platform Patients with SVC isolation (n) Acute SVC isolation, % Phrenic injury Permanent atrioventricular (AV) block / sinus-node dysfunction (SND) Median follow-up Workflow comparison
Ollitrault et al. 2024 [11] Pentaspline (Farapulse) 105 100% None None NR No
Pierucci et al. 2025 [12] Pentaspline + ICE guidance 616 100% None None NR No
Papakonstantinou et al. 2026 [13] Volt™ balloon-in-basket + 3D mapping 1 (technical note) 100% None None NR No
Tilz et al. 2026 [14] Volt™ balloon-in-basket (initial workflow report) 10 100% None None NR No
Present series Volt™ balloon-in-basket + EnSite™ X 3D mapping 53 (consecutive) 100% None None 84 days (IQR 50–196) Yes — two workflows + sensitivity analysis

NR = not reported (the cited source did not report a quantitative median follow-up duration for the SVC-isolation subgroup). The “Phrenic injury” and “Permanent AV block / SND” columns denote persistent events; transient, self-resolving phrenic-nerve stunning and/or sinus-node dysfunction were reported intra-procedurally in several series (including Ollitrault, Pierucci, and Tilz) and in the present cohort, and resolved without sequelae

AF atrial fibrillation, AV atrioventricular, IQR interquartile range, LVEF left ventricular ejection fraction, PFA pulsed-field ablation, PVI pulmonary vein isolation, RA right atrium, SVC superior vena cava

Safety considerations and the transient AV-conduction event

The absence of phrenic-nerve injury in our cohort is consistent with preclinical data showing relative sparing of neural and venous tissue with PFA-based thoracic vein isolation [7]. However, a recent prospective study using compound motor action potential (CMAP) monitoring [16] reported a 40.6% incidence of intra-procedural phrenic-nerve injury and 24% persistent injury at discharge after pulsed-field pulmonary vein isolation. These findings indicate that phrenic-nerve injury with PFA is not negligible, and that active phrenic-nerve screening — as performed in Workflow 1 of the present cohort — is a reasonable, safety-oriented practice. Nevertheless, transient electrophysiological effects can still occur near conduction tissue. In our study, one Workflow 1 patient developed transient junctional rhythm immediately during SVC isolation, consistent with transient sinus-node dysfunction. The event resolved spontaneously without intervention, suggesting a reversible functional effect rather than permanent injury. This sole event arose during a nominal-energy application; no SVC-isolation–attributable electrophysiological event occurred among the 25 Workflow 2 patients treated exclusively with low-energy applications — an observation consistent with, though not proof of, the safety rationale for a low-energy-only strategy. This observation is consistent with preclinical findings and early clinical experience with PFA close to the atrioventricular conduction system [7, 17], and supports careful mapping, avoidance of the sinus node region, and continuous rhythm surveillance during SVC ablation.

Workflow comparison: temporal vs. workflow-attributable effects

The shorter total procedure and fluoroscopy times observed in Workflow 2 should not be interpreted as a direct effect of the workflow change. The two workflows were applied to consecutive — not concurrent — cohorts. During the transition, the operator was simultaneously accumulating experience with the Volt™ platform, and an improved iteration of the Volt™ catheter was introduced on 20 January 2026. When the comparison is restricted to a single catheter-platform era, the procedure- and fluoroscopy-time differences disappear (p = 0.94 and p = 0.35), whereas the SVC-specific differences remain significant. The differences that genuinely reflect the workflow change are therefore confined to SVC-specific metrics: the exclusive use of low-energy PFA in Workflow 2, the absence of phrenic-nerve pacing, a statistically significant increase in the number of PFA applications, and a modestly longer total SVC isolation time.

Clinical implications

Our data support the feasibility and acute safety of Volt™-based SVC isolation as an adjunct to pulmonary vein isolation in selected patients. Once operator experience is established, the simplified low-energy-only protocol offers practical advantages in procedural efficiency. The randomised evidence on empiric adjunctive SVC isolation is derived from paroxysmal AF cohorts and is mixed [18, 19]. Our cohort is predominantly persistent or long-standing persistent AF; recent multielectrode-PFA experience in this population has documented acceptable acute safety [20]. The present data speak only to whether adjunctive SVC isolation can be performed feasibly and with acceptable acute safety in this population, which they support. Whether adjunctive SVC isolation confers incremental freedom from arrhythmia in persistent AF is unresolved and warrants a dedicated randomised trial in that specific phenotype.

Limitations

This study has several limitations. It is a retrospective single-centre series of modest size, in which SVC isolation was performed alongside pulmonary vein isolation and, in some patients, additional ablation; the independent clinical effect of SVC isolation cannot therefore be determined. The two workflows represent sequential — not concurrent — cohorts. The workflow transition was temporally collinear with three co-varying factors: (i) an operator learning curve, (ii) the introduction of an improved Volt™ catheter iteration on 20 January 2026, and (iii) a broadening of the institutional indication for SVC isolation from discretionary to routine. These three confounders cannot be fully separated. Total procedure and fluoroscopy time differences between the two workflow cohorts reflect predominantly these temporal factors, and only the SVC-specific metrics can be interpreted as workflow-attributable — a conclusion supported by the pre-specified within-platform sensitivity analysis. Durability of SVC isolation was not assessed by systematic invasive re-mapping. Phrenic-nerve injury was assessed by intra-procedural fluoroscopic monitoring of diaphragmatic motion and by clinical follow-up; no compound motor action potential (CMAP) recording was performed, so subclinical phrenic-nerve injury of the kind reported by Chéhirlian et al. [16] cannot be excluded. The median clinical follow-up of 84 days approaches but does not yet reach the 3–6-month window in which late phrenic-nerve dysfunction characteristically manifests; late phrenic-nerve injury and late conduction-system events cannot be assessed from the present dataset.

Conclusions

SVC isolation with the Volt™ balloon-in-basket PFA catheter is feasible and appears acutely safe in a consecutive cohort of 53 patients. Both standardised workflows achieved 100% acute isolation, with no phrenic-nerve injury and no permanent atrioventricular block in either group. Workflow-attributable differences were confined to SVC-specific metrics (exclusive low-energy PFA use, no phrenic-nerve pacing, and modestly more applications with longer SVC isolation time in Workflow 2). Shorter total procedure and fluoroscopy times in the later cohort reflected operator learning and the improved Volt™ catheter (20 January 2026) rather than the workflow change. Durability and rhythm outcomes require dedicated follow-up study.

Supplementary Information

Below is the link to the electronic supplementary material.

10840_2026_2409_MOESM1_ESM.xlsx (21.1KB, xlsx)

Supplementary File S1 (Microsoft Excel workbook): SVC_isolation_stats_workbook.xlsx —contains the de-identified per-patient dataset, per-group descriptive statistics, Mann–Whitney U and Fisher's exact test outputs, and the underlying calculations supporting all numerical values in Tables 1 and 2 of the main manuscript (XLSX 21.1 KB)

Acknowledgements

None.

Author contributions

Conceptualization: MW; Investigation: MW; Data curation: MW, PB; Formal analysis: MW, PB; Writing — original draft: MW; Writing — review and editing: PB, AG; Supervision: MW. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and approved by the Bioethics Committee at the Medical University of Lublin (Resolution KE-0254/79/04/2024 of 25 April 2024, amending the original Resolution KE-0254/154/05/2023), which specifically covers atrial fibrillation ablation using pulsed-field ablation with additional applications beyond pulmonary vein isolation. All patients provided written informed consent for the ablation procedure and for the use of de-identified clinical data for research purposes, in accordance with the Bioethics Committee approval.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66. 10.1056/NEJM199809033391003. [DOI] [PubMed] [Google Scholar]
  • 2.Tsai CF, Tai CT, Hsieh MH, Lin WS, Yu WC, Ueng KC, Ding YA, Chang MS, Chen SA. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation. 2000;102(1):67–74. 10.1161/01.cir.102.1.67. [DOI] [PubMed] [Google Scholar]
  • 3.Chen SA, Tai CT, Yu WC, Chen YJ, Tsai CF, Hsieh MH, Chen CC, Prakash VS, Ding YA, Chang MS. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 1999;10(3):328–35. . 10.1111/j.1540-8167.1999.tb00679.x. [DOI] [PubMed] [Google Scholar]
  • 4.Tzeis S, Gerstenfeld EP, Kalman J, Saad E, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen M, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O’Neill M, Pak HN, Piccini JP, Pürerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. J Interv Card Electrophysiol. 2024;67(5):921–1072. 10.1007/s10840-024-01771-5. [DOI] [PubMed] [Google Scholar]
  • 5.Reddy VY, Neuzil P, Koruth JS, Petru J, Funasako M, Cochet H, Sediva L, Chovanec M, Dukkipati SR, Jais P. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74(3):315–26. 10.1016/j.jacc.2019.04.021. [DOI] [PubMed] [Google Scholar]
  • 6.Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, Cochet H, Minami K, Breskovic T, Sikiric I, Sediva L, Chovanec M, Koruth J, Jais P. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614–27. 10.1016/j.jacep.2021.02.014. [DOI] [PubMed] [Google Scholar]
  • 7.Koruth J, Kuroki K, Iwasawa J, Enomoto Y, Viswanathan R, Brose R, Buck ED, Speltz M, Dukkipati SR, Reddy VY. Preclinical evaluation of pulsed field ablation: electrophysiological and histological assessment of thoracic vein isolation. Circ Arrhythm Electrophysiol. 2019;12(12):e007781. 10.1161/CIRCEP.119.007781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chun KJ, Miklavčič D, Vlachos K, Bordignon S, Scherr D, Jais P, Schmidt B. State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective. Europace. 2024;26(6):euae134. doi:10.1093/europace/euae134. Erratum in: Europace. 2024 Jul 2;26(7):euae182. doi:10.1093/europace/euae182. [DOI] [PMC free article] [PubMed]
  • 9.Sanders P, Healy S, Emami M, Kotschet E, Miller A, Kalman JM. Initial clinical experience with the balloon-in-basket pulsed field ablation system: acute results of the VOLT CE mark feasibility study. Europace. 2024;26(5):euae118. 10.1093/europace/euae118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tilz RR, Chierchia GB, Gunawardene M, Sanders P, Haqqani H, Kalman J, Healy S, Pürerfellner H, Neuzil P, Asensi JO, Loh P, Reddy VY, Knecht S, Jesser E, Dirckx N, Miller A, Walker D, Lakkireddy D. Safety and effectiveness of the first balloon-in-basket pulsed field ablation system for the treatment of atrial fibrillation: VOLT CE Mark Study 6-month results. Europace. 2025;27(4):euaf072. 10.1093/europace/euaf072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ollitrault P, Chaumont C, Font J, Manninger M, Conti S, Matusik PT, Mulder BA, Ferchaud V, Pellissier A, Al Khoury M, Milliez P, Champ-Rigot L, Anselme F. Superior vena cava isolation using a pentaspline pulsed-field ablation catheter: feasibility and safety in patients undergoing atrial fibrillation catheter ablation. Europace. 2024;26(7):euae160. 10.1093/europace/euae160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pierucci N, La Fazia VM, Mohanty S, Schiavone M, Doty B, Gabrah K, Della Rocca DG, Burkhardt JD, Al-Ahmad A, Di Biase L, Casella M, Russo AD, Nair D, Mansour M, Tondo C, Natale A. Results of ICE-guided isolation of the superior vena cava with pulsed field ablation. JACC Clin Electrophysiol. 2025;11(4):752–60. 10.1016/j.jacep.2024.11.009. [DOI] [PubMed] [Google Scholar]
  • 13.Papakonstantinou PE, O’Brien J. Superior vena cava isolation with 3D mapping using a novel balloon-in-basket pulsed field ablation catheter. J Interv Card Electrophysiol. 2026;69(3):327–8. 10.1007/s10840-025-02158-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tilz RR, Ukita K, Eitel C, Kuck KH, Hatahet S, Wenzel JP. How to isolate the superior vena cava using balloon-in-basket pulsed field ablation system: Standardized workflow and initial results. Heart Rhythm O2. 2026;7(4):706–12. 10.1016/j.hroo.2026.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mondésert B, Andrade JG, Khairy P, Guerra PG, Dyrda K, Macle L, Rivard L, Thibault B, Talajic M, Roy D, Dubuc M, Shohoudi A. Clinical experience with a novel electromyographic approach to preventing phrenic nerve injury during cryoballoon ablation in atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(4):605–11. 10.1161/CIRCEP.113.001238. [DOI] [PubMed] [Google Scholar]
  • 16.Chéhirlian L, Koutbi L, Mancini J, Hourdain J, Richard-Vitton R, Wilkin M, Deharo JC, Maille B, Franceschi F. High incidence of phrenic nerve injury in patients undergoing pulsed field ablation for atrial fibrillation. Heart Rhythm. 2025;22(12):e1206–13. 10.1016/j.hrthm.2025.08.010. [DOI] [PubMed] [Google Scholar]
  • 17.Zeng R, Li F, Jiang J, Cui K, Yang Q, Gao J, Zhu X, Shi T, Li W, Tong Y, Zhang Q, Hu H, Fu H. The Safety and Feasibility of Pulsed-Field Ablation in Atrioventricular Nodal Re-Entrant Tachycardia: First-in-Human Pilot Trial. JACC Clin Electrophysiol. 2024;10(1):82–92. 10.1016/j.jacep.2023.08.030. [DOI] [PubMed] [Google Scholar]
  • 18.Mariani MV, Palombi M, Jabbour JP, Pierucci N, Cipollone P, Piro A, Chimenti C, Miraldi F, Vizza CD, Lavalle C. Usefulness of empiric superior vena cava isolation in paroxysmal atrial fibrillation ablation: a meta-analysis of randomized clinical trials. J Interv Card Electrophysiol. 2025;68(1):93–100. 10.1007/s10840-024-01867-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Shen W, Zhang Y, Qian W, Li C, Wang C, Li W, Li J, Chen J, Wei Y, Liu Y, Zhao Y, Xu W. Pulmonary vein isolation with or without empiric superior vena cava isolation in patients undergoing ablation for paroxysmal atrial fibrillation: the randomized ESVCI-AF trial. Europace. 2025;27(9):euaf175. 10.1093/europace/euaf175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Della Rocca DG, Sorgente A, Pannone L, Cespón-Fernández M, Vetta G, Almorad A, Bala G, Del Monte A, Ströker E, Sieira J, Doundoulakis I, Mouram S, Audiat C, Monaco C, Mohanty S, Scacciavillani R, Marcon L, Nakasone K, Zaher W, Overeinder I, Boveda S, La Meir M, Natale A, Sarkozy A, de Asmundis C, Chierchia GB. Multielectrode catheter-based pulsed field ablation of persistent and long-standing persistent atrial fibrillation. Europace. 2024;26(10):euae246. 10.1093/europace/euae246. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

10840_2026_2409_MOESM1_ESM.xlsx (21.1KB, xlsx)

Supplementary File S1 (Microsoft Excel workbook): SVC_isolation_stats_workbook.xlsx —contains the de-identified per-patient dataset, per-group descriptive statistics, Mann–Whitney U and Fisher's exact test outputs, and the underlying calculations supporting all numerical values in Tables 1 and 2 of the main manuscript (XLSX 21.1 KB)

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Journal of Interventional Cardiac Electrophysiology are provided here courtesy of Springer

RESOURCES